Branded Legacy
Branded Legacy, Inc. (OTC: BLEG) is a publicly traded Melbourne, Florida-based holding company that divested all prior biotech, wellness, and digital subsidiaries in December 2025 and is now repositioning as a serial acquirer of AI technology companies serving healthcare, manufacturing, and retail verticals.
- Company typePublic
- Founded1981
- HeadquartersCharlotte, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Branded Legacy does
Branded Legacy, Inc. (OTC Pink: BLEG) is a publicly traded holding company headquartered in Melbourne, Florida. Through December 2025 the company operated a portfolio of acquired subsidiaries spanning plant-based pharmaceuticals (Sycamore BioPharma, MariJ Pharmaceuticals), intranasal drug delivery R&D (BioLegacy Evaluative Group — naloxone spray and an air-driven delivery device at the FDA Pre-ANDA stage), sober-social retail (Pau Hana Kava Bar, contributing approximately $125,000 in Q3 revenue), and digital services (Rocket Web Development and Design). The company's stated go-to-market combined consumer retail, wholesale/distributor licensing for CBD across multiple states, pharma distribution through healthcare providers, and direct enterprise sales.
In December 2025, shareholder Dr. Jamie Forrest acquired a controlling interest and executed a complete restructuring: all prior subsidiaries were divested, legacy management was replaced, and approximately $2 million in legacy convertible debt was retired. Jeffery Robison was appointed CEO and Sole Director in April 2026 and announced a strategic pivot toward acquiring multiple AI technology companies targeting healthcare diagnostics, manufacturing automation and supply chain optimization, and retail personalization. A 1-for-2000 reverse stock split became effective June 2, 2026.
As of the input data, Branded Legacy is an operating but effectively pre-revenue public shell with 1–10 employees and no active product-generating subsidiaries. The company's monetizable assets consist of its listed equity instrument, $1 million line of credit, and stated intent to consummate AI acquisitions; commercial credibility for the AI strategy rests on future M&A execution rather than existing technical capability.
Branded Legacy firmographics
Firmographics- Name
- Branded Legacy
- Legal name
- Bio Legacy Evaluative Group
- Website
- https://brandedlegacy.com
- Company type
- Public
- Founded year
- 1981
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Branded Legacy, Inc. (OTC: BLEG) is a publicly traded Melbourne, Florida-based holding company that divested all prior biotech, wellness, and digital subsidiaries in December 2025 and is now repositioning as a serial acquirer of AI technology companies serving healthcare, manufacturing, and retail verticals.
- Ownership category
- akta.pro rank
Branded Legacy industry classification
Industry- Product category
- AI-Powered Enterprise Solutions
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Eye, Ear & Nasal Care OTC (Eye Drops, Ear Drops/Wax Removal, Saline Sprays) (CRADAMAG)
- akta.pro secondary industries
- OTC & Consumer Health Distributors (HLAIAJAC), Sleep, Stress & Mood OTC (Sleep Aids, Melatonin OTC, Calm/Stress Relief) (CRADAMAJ)
Keywords
Where Branded Legacy is headquartered
LocationHeadquarters
- HQ city
- Charlotte
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Branded Legacy business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Revenue model
- Kava Bar Operations (Pau Hana): Revenue generated from kava bar operations including beverage sales. The company posted over $125,000 in third-quarter revenues and plans to expand through acquisition of additional high-performing locations.
- Biotechnology and Pharmaceutical Development: Revenue from development and potential commercialization of plant-based pharmaceuticals, CBD products, and drug delivery systems. Includes licensing of intellectual property and operational licenses across multiple states.
- CBD and Wellness Products: Revenue from CBD and wellness industry operations including physical assets, intellectual property, operational tools, and mobile processing units across multiple states.
- Web Development Services: Revenue from Rocket Web Development and Design (RWDD) subsidiary providing digital capabilities and web solutions to subsidiaries and clients.
- AI Technology Solutions: Revenue from AI-driven solutions and services targeting healthcare, manufacturing, and retail industries with transformative efficiencies.
Go-to-market motion1 record
Distribution channels4 records
Marketing channels5 records
Branded Legacy product offering
Product offeringCore offering
Branded Legacy, Inc. (OTC: BLEG) is a publicly traded holding company focused on AI technology solutions for the healthcare, manufacturing, and retail industries, acquired and integrated through a strategic acquisition-based growth model. The company additionally develops pharmaceutical products, most notably an intranasal naloxone spray for opioid overdose reversal supported by a proprietary air-driven, needle-free intranasal drug delivery device platform.
Product overview
Branded Legacy, Inc. (OTC: BLEG) is a biotechnology holdings company that underwent a complete restructuring in December 2025 under new leadership by shareholder Dr. Jamie Forrest. All previous subsidiaries were divested. The company is now strategically focused on acquiring multiple AI tech companies, targeting select industries that stand to gain from AI adoption. The current product portfolio includes BioLegacy Evaluative Group's intranasal drug delivery technologies, specifically the intranasal naloxone spray and air-driven intranasal drug delivery device, which represent the company's active pharmaceutical development initiatives aimed at addressing the opioid crisis.
Differentiator
Problem solved
Functional benefit
Products and services
- Intranasal Naloxone Spray Intranasal naloxone spray developed to rapidly reverse opioid overdoses, designed for use by first responders, healthcare providers, and community distribution programs targeting the opioid crisis.
- Air-Driven Intranasal Drug Delivery Device Proprietary air-driven, needle-free intranasal drug delivery device platform intended to deliver pharmaceuticals such as naloxone without injection, targeted at healthcare providers, emergency responders, and pharmaceutical partners.
Quantifiable outcome
- Global kava market growing from $1.6 billion to $3.0 billion by 2033 at 9.3% CAGR
Companies that use Branded Legacy
Customer profileSegments3 records
Ideal customer profiles3 records
Branded Legacy technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
Feature3 records
Branded Legacy partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered minor and core.
- Botany Evolution LLCminorStrategic partner in $150 million kava manufacturing investments as part of the global kava root extract market development. Both companies are key players in the emerging plant-based anxiety and stress-relief solutions market.
- CuraScientific Corp.minorStrategic partner in $150 million kava manufacturing investments as part of the global kava root extract market development. Collaboration focused on meeting rising consumer interest in plant-based wellness solutions.
- Pau Hana Kava BarcoreBranded Legacy Inc acquired Pau Hana Kava Bar as a subsidiary. The acquisition contributes over $125,000 in quarterly revenues with plans for expansion through a roll-up strategy of additional high-performing kava bars, focusing on the sober-social and functional beverage movement in Florida and beyond.
- Sycamore BioPharma, Inc.coreAcquisition of Sycamore BioPharma, Inc., a developer of plant-based pharmaceuticals, which expanded Branded Legacy's assets, inventory, and clinical trials capabilities. The acquisition included appointment of Dr. Mark T. Hamann as Director of Clinical Trials to support pharmaceutical development and FDA approval processes.
- MariJ Pharmaceuticals, Inc.coreLargest acquisition to date involving extensive assets and operational licenses across multiple states. Deal includes physical assets, intellectual property, operational tools, and mobile processing units designed to enhance expansion in the CBD and wellness industry, significantly boosting operational capacity and geographic reach.
- Rocket Web Development and Design (RWDD)minorAcquisition of Rocket Web Development and Design to enhance digital capabilities and support Branded Legacy's strategic focus on expanding web solutions for subsidiaries and clients.
Scale indicators9 records
Recent moves7 records
Expansion highlights4 records
Branded Legacy competitors and assessment
Company assessmentEmerging players
- Tarsus Pharmaceuticals: Small-cap pharma with innovative specialty therapeutics in development. Comparable as a sub-scale public pharma navigating FDA pathways.
- Zomedica Pharmaceuticals: Micro-cap public health company that has undergone multiple strategic pivots and acquisitions. Comparable in scale and pattern of repeated restructuring under new leadership.
- Enveric Biosciences: Small-cap biotech pivoting business focus with limited operating revenue. Comparable as a micro-cap public shell undergoing strategic reset with new management.
- Tonix Pharmaceuticals: Small-cap clinical pharma with proprietary intranasal and drug-delivery programs. Comparable as a micro-cap pharma pursuing innovative delivery methods.
- Adamis Pharmaceuticals: Small-cap specialty pharma developing and commercializing novel therapeutics. Comparable in scale and specialty pharma orientation.
- Virpax Pharmaceuticals: Clinical-stage small-cap pharma developing novel drug delivery platforms including intranasal formulations. Comparable as a sub-scale pharma with proprietary delivery technology.
- Chembio Diagnostics: Small-cap diagnostics and specialty pharma with OTC and point-of-care products. Comparable as a micro-cap public health-products company.
Direct peers
- Aytu BioPharma: Small-cap specialty pharmaceutical company commercializing prescription and consumer health products including intranasal therapies. Comparable scale, business model, and target markets.
- Emergent BioSolutions: Manufacturer of Narcan, the leading intranasal naloxone spray for opioid overdose reversal. Most directly comparable competitor to Branded Legacy's intranasal naloxone development program.
- Amphastar Pharmaceuticals: Generic injectable and intranasal pharmaceutical manufacturer, including a competing naloxone nasal spray. Comparable as a small-cap specialty pharma with intranasal drug delivery focus.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Branded Legacy social profiles
Digital presenceBranded Legacy financial estimates
Financial estimateRevenue estimate
Valuation estimate
Branded Legacy leadership team
Management profileNumber of profiles
Profiles1 record
Branded Legacy funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Branded Legacy M&A and investment
M&A and investmentM&A7 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Branded Legacy
What does Branded Legacy do?
Branded Legacy, Inc. (OTC: BLEG) is a publicly traded holding company focused on AI technology solutions for the healthcare, manufacturing, and retail industries, acquired and integrated through a strategic acquisition-based growth model. The company additionally develops pharmaceutical products, most notably an intranasal naloxone spray for opioid overdose reversal supported by a proprietary air-driven, needle-free intranasal drug delivery device platform.
Is Branded Legacy a public or private company?
Branded Legacy is a public company. It is classified as public and is currently operating.
When was Branded Legacy founded?
Branded Legacy was founded in 1981. It employs 1 to 10 people.
Where is Branded Legacy based?
Branded Legacy is headquartered in Charlotte, United States, in the North America region.
How does Branded Legacy make money?
Five revenue lines are on record. Kava Bar Operations (Pau Hana) is the primary driver. The others are biotechnology and Pharmaceutical Development, CBD and Wellness Products, web Development Services and AI Technology Solutions.
Who are Branded Legacy's main competitors?
Emerging players on record are Tarsus Pharmaceuticals, Zomedica Pharmaceuticals, Enveric Biosciences, Tonix Pharmaceuticals, Adamis Pharmaceuticals, Virpax Pharmaceuticals and Chembio Diagnostics. Direct peers are Aytu BioPharma, Emergent BioSolutions and Amphastar Pharmaceuticals.
Does Branded Legacy have an API?
No public API is recorded for Branded Legacy.
What industry is Branded Legacy in?
Branded Legacy's product category is AI-Powered Enterprise Solutions. Its primary akta.pro industry code is CRADAMAG, Eye, Ear & Nasal Care OTC (Eye Drops, Ear Drops/Wax Removal, Saline Sprays), with a secondary code of HLAIAJAC, OTC & Consumer Health Distributors. Its NAICS code is 325412 and its SIC code is 2834.